Henderson Molly's Form 4 filing
Phathom Pharmaceuticals, Inc. (PHAT) · filed Jan 22, 2024
- Accession no.
- 0001209191-24-002021
- Filed
- Jan 22, 2024
- Trade date
- Jan 18-19, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market sales total $48.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Henderson MollyCIK 0001363812 | Officer (CFO and CBO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 19, 2024 | Common Stock | SSaleDisposed | −6,307 | $7.75 | −$48,879.25 | 98,698 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 18, 2024 | Common Stock | AGrant or awardAcquired | +120,000 | $0.00 | $0 | 120,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.